Citations

Clear

2511 citation(s) found for "Yang, Ge".

Cervical laminoplasty versus laminectomy and posterior cervical fusion for cervical myelopathy: propensity-matched analysis of 24-month outcomes from the Quality Outcomes Database
Mummaneni, Praveen V. , Chou, Dean , Bydon, Mohamad , Bisson, Erica F. , Shaffrey, Christopher I. , Gottfried, Oren N., Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Buchholz, Avery L., Tumialán, Luis M. , Turner, Jay D. , Michalopoulos, Giorgos D. , Sherrod, Brandon A. , Haid, Regis W., Chan, Andrew K. , Michalopoulos, Giorgos , Yang, Eunice, Park, Paul , Agarwal, Nitin

Mayo Clinic

Journal of Neurosurgery: Spine | August 12, 2023 | Volume: 39 | Issue: 5 | Pages: 671-681

10.3171/2023.6.spine23345 | PMID 37728378 Get It

OBJECTIVE Compared with laminectomy with posterior cervical fusion (PCF), cervical laminoplasty (CL) may result in different outcomes for those operated on for cervical spondylotic myelopathy (CSM). The aim of this study was to compare 24-month patient-reported outcomes (PROs) for laminoplasty versus PCF by using the Quality Outcomes Database (QOD) CSM data set. METHODS This was a retrospective study using an augmented data set from the prospectively collected QOD Registry Cervical Module. Patients undergoing laminoplasty or PCF for CSM were included. Using the nearest-neighbor method, the authors performed 1:1 propensity matching based on age, operated levels, and baseline modified Japanese Orthopaedic Association (mJOA) and visual analog scale (VAS) neck pain scores. The 24-month PROs, i.e., mJOA, Neck Disability Index (NDI), VAS neck pain, VAS arm pain, EQ-5D, EQ-VAS, and North American Spine Society (NASS) satisfaction scores, were compared. Only cases in the subaxial cervical region were included; those that crossed the cervicothoracic junction were excluded. RESULTS From the 1141 patients included in the QOD CSM data set who underwent anterior or posterior surgery for cervical myelopathy, 946 (82.9%) had 24 months of follow-up. Of these, 43 patients who underwent laminoplasty and 191 who underwent PCF met the inclusion criteria. After matching, the groups were similar for baseline characteristics, including operative levels (CL group: 4.0 ± 0.9 vs PCF group: 4.2 ± 1.1, p = 0.337) and baseline PROs (p > 0.05), except for a higher percentage involved in activities outside the home in the CL group (95.3% vs 81.4%, p = 0.044). The 24-month follow-up for the matched cohorts was similar (CL group: 88.4% vs PCF group: 83.7%, p = 0.534). Patients undergoing laminoplasty had significantly lower estimated blood loss (99.3 ± 91.7 mL vs 186.7 ± 142.7 mL, p = 0.003), decreased length of stay (3.0 ± 1.6 days vs 4.5 ± 3.3 days, p = 0.012), and a higher rate of routine discharge (88.4% vs 62.8%, p = 0.006). The CL cohort also demonstrated a higher rate of return to activities (47.2% vs 21.2%, p = 0.023) after 3 months. Laminoplasty was associated with a larger improvement in 24-month NDI score (−19.6 ± 18.9 vs −9.1 ± 21.9, p = 0.031). Otherwise, there were no 3- or 24-month differences in mJOA, mean NDI, VAS neck pain, VAS arm pain, EQ-5D, EQ-VAS, and distribution of NASS satisfaction scores (p > 0.05) between the cohorts. CONCLUSIONS Compared with PCF, laminoplasty was associated with decreased blood loss, decreased length of hospitalization, and higher rates of home discharge. At 3 months, laminoplasty was associated with a higher rate of return to baseline activities. At 24 months, laminoplasty was associated with greater improvements in neck disability. Otherwise, laminoplasty and PCF shared similar outcomes for functional status, pain, quality of life, and satisfaction. Laminoplasty and PCF achieved similar neck pain scores, suggesting that moderate preoperative neck pain may not necessarily be a contraindication for laminoplasty.
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
Zarif, Talal El , Pond, Gregory R. , Zhuang, Tony , Master, Viraj A. , Nazha, Bassel , Niglio, Scot A. , Simon, Nicholas I. , Hahn, Andrew W. , Pettaway, Curtis A. , Tu, Shi‐Ming, Abdel‐Wahab, Noha , Velev, Maud , Flippot, Ronan , Maruzzo, Marco , Yang, Yuanquan , Rodriguez, Pablo Alvarez, Castellano, Daniel , Velasco, Guillermo de , Roviello, Giandomenico , Antonuzzo, Lorenzo , McKay, Rana R. , Hui, Gavin , Drakaki, Alexandra , Glover, Michael , Khaki, Ali Raza , El‐Am, Edward , Patel, Vaibhav G. , Piedra, A. , Gernone, Angela , Davis, Nancy B. , Matthews, Harrison, Giudice, Giulia Claire , Farolfi, Alberto , Milowsky, Matthew I. , Appleman, Leonard J. , Freeman, Dory , Sonpavde, Guru , El Zarif, Talal , Nazha, Bassel , Hahn, Andrew W , Antonuzzo, Lorenzo , Khaki, Ali Raza , El-Am, Edward , Appleman, Leonard , Choueiri, Toni K , Spiess, Philippe E , Necchi, Andrea , Sonpavde, Guru , Pond, Gregory Russell , Nassar, Amin H. , Tu, Shi‐Ming , Buti, Sebastiano , Mittra, Arjun , Gheeya, Jinesh , Vincenzi, Bruno , Cortellini, Alessio , Drakaki, Alexandra , Adra, Nabil , Mouhieddine, Tarek H. , Harrison, Michael R. , Kanesvaran, Ravindran , Barata, Pedro C. , Lee, Jae‐Lyun , Stahlfeld, Charlotte N. , Kim, Joseph W. , Choueiri, Toni K. , Spiess, Philippe E. , Necchi, Andrea , Apolo, Andrea B

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 11, 2023 | Volume: 115 | Issue: 12 | Pages: 1605-1615

10.1093/jnci/djad155 | PMID 37563779 Get It

Abstract Background Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors. Methods This retrospective study included patients with locally advanced or metastatic penile squamous cell carcinoma receiving immune checkpoint inhibitors between 2015 and 2022 across 24 centers in the United States, Europe, and Asia. Overall survival and progression-free survival were estimated using the Kaplan-Meier method. Objective response rates were determined per Response Evaluation Criteria in Solid Tumours 1.1 criteria. Treatment-related adverse events were graded per the Common Terminology Criteria for Adverse Events, version 5.0. Two-sided statistical tests were used for comparisons. Results Among 92 patients, 8 (8.7%) were Asian, 6 (6.5%) were Black, and 24 (29%) were Hispanic and/or Latinx. Median (interquartile range) age was 62 (53-70) years. In all, 83 (90%) had metastatic penile squamous cell carcinoma, and 74 (80%) had received at least second-line treatment. Most patients received pembrolizumab monotherapy (n = 26 [28%]), combination nivolumab-ipilimumab with or without multitargeted tyrosine kinase inhibitors (n = 23 [25%]), or nivolumab (n = 16 [17%]) or cemiplimab (n = 15 [16%]) monotherapies. Median overall and progression-free survival were 9.8 months (95% confidence interval = 7.7 to 12.8 months) and 3.2 months (95% confidence interval = 2.5 to 4.2 months), respectively. The objective response rate was 13% (n = 11/85) in the overall cohort and 35% (n = 7/20) in patients with lymph node–only metastases. Visceral metastases, Eastern Cooperative Oncology Group (ECOG) performance status of 1 or higher, and a higher neutrophil/lymphocyte ratio were associated with worse overall survival. Treatment-related adverse events occurred in 27 (29%) patients, and 9.8% (n = 9) of the events were grade 3 or higher. Conclusions Immune checkpoint inhibitors are active in a subset of patients with penile squamous cell carcinoma. Future translational studies are warranted to identify patients more likely to derive clinical benefit from immune checkpoint inhibitors.
The use of complementary and alternative medicine for the treatment of gastrointestinal symptoms in Long COVID: a systematic review
Gawey, Brent J. , Yang, Juan , Bauer, Brent A. , Song, Joanne, Gawey, Brent , Bauer, Brent, Wang, Xiao‐Jing

Mayo Clinic

Therapeutic Advances in Chronic Disease | August 11, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/20406223231190548 | PMID 37577106 Get It

Background: Most people with coronavirus disease 2019 (COVID-19) experience resolution of symptoms within days to weeks following initial infection. In a subset of individuals, symptoms persist longer than 4 weeks, known as ‘Long COVID’. Many gastrointestinal (GI) symptoms persist as part of this syndrome; yet, an approach to treatment remains unclear. Prior studies have demonstrated the efficacy of complementary and alternative medicine (CAM) for the treatment of acute COVID-19 infections, but little data exist regarding the potential use of CAM in the treatment of Long COVID. Objectives: Identify CAM approaches useful in treating the GI symptoms of Long COVID. Design: A systematic review of studies reporting on the use of CAM for the treatment of GI symptoms of Long COVID was performed. Data Sources and Methods: Five electronic databases were searched from January 2019 to November 2022. Studies describing the use of CAM to treat GI symptoms of Long COVID were included and assessed by two independent reviewers. Studies not reporting on GI symptoms or using CAM were excluded. Studies chosen for final review underwent quality and bias assessment using predetermined criteria. The extracted data were synthesized utilizing a framework derived from the National Center of Complementary and Integrative Health categories. Results: The initial search yielded 396 articles. After applying the eligibility criteria, a total of four studies (three case reports and one case series) were included for final review. Two studies used nutritional supplements and two studies used traditional Chinese medicine. Reductions in nausea, loss of appetite, diarrhea, acid reflux, epigastric pain, and bloating were reported. Conclusion: This is the first systematic review to explore the role of CAM in treating GI manifestations of Long COVID. The review identified four studies, all reporting reductions in the GI symptoms of Long COVID. Despite the positive studies included in this review, the overall search yielded few results, all of which were non-experimental. As the post-infectious sequelae of COVID-19 become better recognized in the wake of the pandemic, higher-quality clinical studies are needed.
Comprehensive characterization of human brain‐derived extracellular vesicles using multiple isolation methods: Implications for diagnostic and therapeutic applications
Zhang, Zhengrong , You, Yang , Jiang, Peizhou , Wu, Zhiping, DeTure, Michael , Ikezu, Seiko , Peng, Junmin , Ikezu, Tsuneya , DeTure, Michael A, Ikezu, Tsuneya , Yang, You , Yu, Kaiwen , Dickson, Dennis W.

Mayo Clinic

Journal of Extracellular Vesicles | August 11, 2023 | Volume: 12 | Issue: 8 | Pages: No page available

10.1002/jev2.12358 | PMID 37563857 Get It

Abstract Extracellular vesicles (EVs) have emerged as critical mediators of intercellular communication and promising biomarkers and therapeutics in the central nervous system (CNS). Human brain‐derived EVs (BDEVs) provide a comprehensive snapshot of physiological changes in the brain's environment, however, the isolation of BDEVs and the comparison of different methods for this purpose have not been fully investigated. In this study, we compared the yield, morphology, subtypes and protein cargo composition of EVs isolated from the temporal cortex of aged human brains using three established separation methods: size‐exclusion chromatography (SEC), phosphatidylserine affinity capture (MagE) and sucrose gradient ultracentrifugation (SG‐UC). Our results showed that SG‐UC method provided the highest yield and collected larger EVs compared to SEC and MagE methods as assessed by transmission electron microscopy and nanoparticle tracking analysis (NTA). Quantitative tandem mass‐tag (TMT) mass spectrometry analysis of EV samples from three different isolation methods identified a total of 1158 proteins, with SG‐UC showing the best enrichment of common EV proteins with less contamination of non‐EV proteins. In addition, SG‐UC samples were enriched in proteins associated with ATP activity and CNS maintenance, and were abundant in neuronal and oligodendrocytic molecules. In contrast, MagE samples were more enriched in molecules related to lipoproteins, cell‐substrate junction and microglia, whereas SEC samples were highly enriched in molecules related to extracellular matrix, Alzheimer's disease and astrocytes. Finally, we validated the proteomic results by performing single‐particle analysis using the super‐resolution microscopy and flow cytometry. Overall, our findings demonstrate the differences in yield, size, enrichment of EV cargo molecules and single EV assay by different isolation methods, suggesting that the choice of isolation method will have significant impact on the downstream analysis and protein discovery.
Characterization and clinical significance of T follicular helper cells in follicular lymphoma
Tang, Xinyi , Mukherjee, Prithviraj , Ansell, Stephen M. , Yang, Zhi-Zhang , Kim, Hyo Jin , Bhardwaj, Vaishali , Mondello, Patrizia

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 88.04-88.04

10.4049/jimmunol.210.supp.88.04 Get It

Abstract T follicular helper (TFH) cells are a subset of CD4+ T cells that reside within the follicles of secondary lymphoid organs and play an essential role in the germinal center (GC) reaction. To examine the role TFH cells in follicular lymphoma (FL), we first characterized TFH cells using single cell analysis with the high-throughput technologies of mass cytometry (CyTOF) and the Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq). Clustering analysis revealed that TFH cells form subsets with unique phenotypes, and the expression of many common markers including CXCR5, ICOS, IL-21, TOX2, CD57, GZMK, XCL1, XCL2, CXCL13 and CD40L varies on TFH subsets. We found that TFH cells are phenotypically more heterogenous in FL than benign tonsil tissues by both proteomic (n=82) and transcriptomic (n=8) profiling. Each FL patient showed different dominant TFH subsets, in contrast to tonsil donors which were highly homogenous. Some TFH subsets were only present in FL and absent in tonsil tissues, suggesting the existence of FL-specific TFH cells. Cytokines (IL-2, IL12, IL-17 and IL-21) and activated B cells upregulated TFH markers including PD-1, CXCR5 and IL-21 to induce the development of TFH subsets such as IL-21+ or IL-21+IFN-g+ TFH cells, which was inhibited by rapamycin, an immunosuppressor. We observed that the TFH cell frequency significantly correlated with the number of lymphoma B cells. Futhermore, while TFH cells as a whole showed no correlation with prognosis, TFH subsets such as CD57+ TFH cells were significantly associated with an inferior patient outcome. Taken together, our results indicate that TFH cells are highly heterogenous with different tumor-specific TFH subsets present in FL and associated with patient outcomes in FL.
Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Pfeiler, Georg , Hlauschek, Dominik , Mayer, Erica L. , Deutschmann, Christine , Martín, Miguel , Loibl, Sibylle , Balić, Marija , Park, Haeseong , Prat, Aleix , Bajetta, Emilio, Balko, Justin M. , Bellet-Ezquerra, Merixtell, Bliss, Judith M. , Burstein, Harold J. , Fohler, Hannes, Haddad, Tufia C. , Jassem, Jacek , Lee, Soo Chin , Los, Maartje , Mamounas, Eleftherios P. , Morris, Patrick G. , Gal‐Yam, Einav Nili , Ring, Alistair , Shepherd, Lois E. , Thomssen, Christoph , Machacek‐Link, Jana, Schurmans, Céline , Huang, Xin , Gauthier, Eric , Fesl, Christian , Dueck, Amylou C. , Gnant, Michael , Investigators, on behalf of the PALLAS Groups and, Cameron, David , Steger, Guenther G. , Bellet, Meritxell , Dueck, A. C. , Martin, Miguel , Zdenkowski, Nicholas , Loibl, Sibylle , Balic, Marija , Park, Haeseong , Isaacs, Claudine , Wrangle, John M , Bliss, Judith , Burstein, Harold J , Cardoso, Fatima , Foukakis, Theodoros , Gelmon, Karen A , Goetz, Matthew P , Haddad, Tufia C , Iwata, Hiroji , Jassem, Jacek , Lee, Soo-Chin , Mamounas, Eleftherios P. , Miller, Kathy D , Munzone, Elisabetta , Gal-Yam, Einav Nili , Shepherd, LE , Singer, Christian F , Thomssen, Christoph , Tseng, Ling-Ming , Valagussa, Pinuccia , Winer, Eric , Wolff, Antonio C , Zoppoli, Gabriele M. , Schurmans, Céline , Huang, Xin , Gauthier, Eric , Fesl, Christian , DeMichele, Angela , Gnant, Michael , Mayer, Erica L , Prat, Aleix , Cameron, David , Strobl, Stephanie , Meisel, Jane Lowe , Isaacs, Claudine , Cardoso, Fátima , Gelmon, Karen A. , Goetz, Matthew P. , Linderholm, Barbro Kristina , Miller, Kathy D. , Singer, Christian F. , Winer, Eric P. , Wolff, Antonio C. , DeMichele, Angela , Investigators, on behalf of the PALLAS Groups and, El-Abed, Sarra , Rugo, Hope S. , Traina, Tiffany A , Werutsky, Gustavo , Wolmark, Norman

Mayo Clinic

Journal of Clinical Oncology | August 9, 2023 | Volume: 41 | Issue: 33 | Pages: 5118-5130

10.1200/jco.23.00126 | PMID 37556775 Get It

PURPOSE BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of the global randomized PALLAS trial investigates the impact of BMI on the side-effect profile, treatment adherence, and efficacy of palbociclib. METHODS Patients were categorized at baseline according to WHO BMI categories. Neutropenia rates were assessed with univariable and multivariable logistic regression. Time to early discontinuation of palbociclib was analyzed with Fine and Gray competing risk models. Unstratified Cox models were used to investigate the association between BMI category and time to invasive disease-free survival (iDFS). 95% CIs were derived. RESULTS Of 5,698 patients included in this analysis, 68 (1.2%) were underweight, 2,082 (36.5%) normal weight, 1,818 (31.9%) overweight, and 1,730 (30.4%) obese at baseline. In the palbociclib arm, higher BMI was associated with a significant decrease in neutropenia (unadjusted odds ratio for 1-unit change, 0.93; 95% CI, 0.91 to 0.94; adjusted for age, race ethnicity, region, chemotherapy use, and Eastern Cooperative Oncology Group at baseline, 0.93; 95% CI, 0.92 to 0.95). This translated into a significant decrease in treatment discontinuation rate with higher BMI (adjusted hazard ratio [HR] for 10-unit change, 0.75; 95% CI, 0.67 to 0.83). There was no significant improvement in iDFS with the addition of palbociclib to ET in any weight category (normal weight HR, 0.84; 95% CI, 0.63 to 1.12; overweight HR, 1.10; 95% CI, 0.82 to 1.49; and obese HR, 0.95; 95% CI, 0.69 to 1.30) in this analysis early in follow-up (31 months). CONCLUSION This preplanned analysis of the PALLAS trial demonstrates a significant impact of BMI on side effects, dose reductions, early treatment discontinuation, and relative dose intensity. Additional long-term follow-up will further evaluate whether BMI ultimately affects outcome.
P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY
Manier, Salomon , Mateos, María‐Victoria , Munshi, Nikhil C. , Arnulf, Bertrand , Vij, Ravi , Broijl, Annemiek , Sborov, Douglas W. , Iida, Shinsuke , Truppel-Hartmann, Anna, Yang, Zhihong, Piasecki, Julia , Felten, Jasper, Caia, Andrea, Rodríguez‐Otero, Paula , Einsele, Hermann , Bahlis, Nizar Jacques , Ailawadhi, Sikander , Nooka, Ajay K. , Abrahamsen, Ingerid Weum , Jagannath, Sundar , Benjamin, Reuben , Gergis, Usama , Cook, Mark , Baz, Rachid

Mayo Clinic

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e3385948

10.1097/01.hs9.0000970368.33859.48 Get It

P1215: CHARACTERIZATION AND CLINICAL SIGNIFICANCE OF T FOLLICULAR HELPER SUBSETS IN FOLLICULAR LYMPHOMA
Tang, Xinyi , Mukherjee, Prithviraj , Novak, Anne J. , Ansell, Stephen M. , Yang, Zhi-Zhang , Kim, Hyo Jin , Bhardwaj, Vaishali , Mondello, Patrizia , Villasboas, José C.

Mayo Clinic

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e5464225

10.1097/01.hs9.0000971756.54642.25 Get It

S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS
Patel, Krina K. , Manier, Salomon , Solomon, Scott R. , Chen, Christine , Delforge, Michel, Larsen, Jeremy T. , Suzuki, Kenshi , Truppel-Hartmann, Anna, Yang, Zhihong, Piasecki, Julia , Felten, Jasper, Caia, Andrea, Mateos, María‐Victoria , Rodríguez‐Otero, Paula , Baz, Rachid , Raab, Marc S. , Cavo, Michèle , Callander, Natalie S. , Costa, Luciano J. , Moreau, Philippe , Raje, Noopur , Scheid, Christof , Pabst, Thomas , Cook, Mark , Giralt, Sergio

Mayo Clinic

HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e369897b

10.1097/01.hs9.0000967692.36989.7b Get It

NCCN Guidelines® Insights: Survivorship, Version 1.2023
Sanft, Tara , Ansbaugh, Shannon, Ballinger, T.J., Demark‐Wahnefried, Wendy , Dickinson, Kristin , Fairman, Nathan, Felciano, Josephine, Flores, Tessa , Gabel, Nicolette , Goldman, Mindy, Henry, N. Lynn , Hill‐Kayser, Christine E. , Koura, Divya, Lee, Kimberly , McDonough, Allison L. , Melisko, Michelle , Mooney, Kathi , Moryl, Natalie , Neuman, Heather B. , Patel, Chirayu G. , Peterson, Lindsay L. , Porpiglia, Andrea S., Rodriguez, Maria Alma , Schapira, Lidia , Smith, Sophia K. , Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Tevaarwerk, Amyé , Henry, N Lynn , Demark-Wahnefried, Wendy , Day, Andrew T. , Armenian, Saro H. , Baker, Kevin Scott , Friedman, Debra L. , Hudson, Melissa M. , Moore, Halle C. F. , O’Connor, Tracey L. , Overholser, Linda , Paskett, Electra D. , Pirl, William F. , Schwartz, Anna L. , Yang, Eric H.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 7, 2023 | Volume: 21 | Issue: 8 | Pages: 792-803

10.6004/jnccn.2023.0041 | PMID 37549906 Get It

The NCCN Guidelines for Survivorship are intended to help healthcare professionals address the complex and varied needs of cancer survivors. The NCCN Guidelines provide screening, evaluation, and treatment recommendations for psychosocial and physical problems resulting from adult-onset cancer and its treatment; recommendations to help promote healthy behaviors and immunizations in survivors; and a framework for care coordination. These NCCN Guidelines Insights summarize recent guideline updates and panel discussions pertaining to sleep disorders, fatigue, and cognitive function in cancer survivors.